Rajnish Saini

发表

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

Piotr Ponikowski, Gerasimos Filippatos, Elaine Unemori, 2013, The Lancet.

Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial

D. Webb, J. Fallowfield, P. Hayes, 2017, PLoS medicine.

The RELAXin in Acute Heart Failure (RELAX-AHF) Trial

P. Ponikowski, G. Filippatos, G. Felker, 2012 .

RELAX-REPEAT: A Multicenter, Prospective, Randomized, Double-Blind Study Evaluating the Safety and Tolerability of Repeat Doses of Serelaxin in Patients with Chronic Heart Failure

L. Gullestad, Yaqin Wang, J. Teerlink, 2016 .

The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure.

W. Laskey, G. Fonarow, B. Hammill, 2019, The American journal of cardiology.

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.

P. Ponikowski, G. Filippatos, G. Felker, 2013, Journal of the American College of Cardiology.

Development of a conceptual model and patient-reported outcome measures for assessing symptoms and functioning in patients with heart failure

V. Sikirica, R. von Maltzahn, K. Benjamin, 2020, Quality of Life Research.

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.

P. Ponikowski, G. Filippatos, G. Felker, 2013, Journal of the American College of Cardiology.

Replication Study: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

Timothy M. Errington, J. Fallowfield, E. Iorns, 2018, eLife.